Absci Corporation (ABSI) Earnings
Absci Corporation is expected to report next earnings on November 16, 2026 (in NaN days), with a consensus EPS estimate of $-0.15. ABSI has beaten EPS estimates in 2 of its last 12 reported quarters (average surprise -9.6% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 11, 2026 | $-0.19 | $-0.18 | +5.8% | $300000 | -67.4% |
| May 7, 2026 | $-0.20 | $-0.19 | +5.0% | $215000 | -84.5% |
| Mar 24, 2026 | $-0.16 | $-0.23 | -43.8% | $650000 | -54.2% |
| Nov 12, 2025 | $-0.19 | $-0.20 | -5.3% | $378000 | -72.6% |
| Aug 12, 2025 | $-0.19 | $-0.24 | -26.3% | $593000 | -88.5% |
| Mar 18, 2025 | $-0.22 | $-0.25 | -13.6% | $665000 | -86.3% |
| Aug 14, 2024 | $-0.19 | $-0.22 | -15.8% | $1M | -33.5% |
| Mar 21, 2024 | $-0.23 | $-0.25 | -8.7% | $338000 | -67.2% |
| Nov 14, 2023 | $-0.23 | $-0.24 | -4.3% | $744000 | -66.0% |
| Aug 14, 2023 | $-0.24 | $-0.27 | -12.5% | $3M | +38.2% |
| May 15, 2023 | $-0.24 | $-0.26 | -8.3% | $1M | -43.5% |
| Aug 11, 2022 | $-0.32 | $-0.32 | +0.0% | $1M | -38.2% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 11, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- **Pipeline & Clinical Progress**: The company released positive interim Phase 1 data for lead candidate ABS-201, which targets the prolactin receptor for pattern hair loss. Interim data confirms favorable safety and tolerability, with an estimated half-life of at least 65 days that supports a potential dosing regimen of 2-3 injections over 6 months. New modeling projects this regimen will achieve >90% receptor occupancy, the threshold the company identifies as required for meaningful clinical efficacy. The multiple ascending dose portion of the Phase 1-2A HEADLINE trial continues to enroll on schedule. Interim proof-of-concept (13-week) data is expected in H2 2026, with full 26-week proof-of-concept data expected in early 2027. ABS-201 development for endometriosis is on track to initiate Phase 2 testing in Q4 2026, with a proof-of-concept readout expected in H2 2027. A preclinical anti-prolactin receptor program ABS-202 is advancing in an undisclosed indication. - **Strategic & Financing Updates**: In June 2026, Abcide completed a $100 million financing, including a $40 million strategic investment from Eli Lilly. A representative from Eli Lilly will join the company's Endometriosis Advisory Board to support ABS-201 clinical development strategy; Abcide retains full rights to the program and plans to develop it independently. The new capital funds planned trial expansion for endometriosis and advances the company's early pipeline. - **AI Platform Capabilities**: Abcide has extended its AI drug discovery platform upstream with the launch of Atlas, an autonomous target identification and validation engine that integrates public literature to surface and triage novel target hypotheses. Output from Atlas flows directly into the company's existing Origin de novo antibody design platform, creating an end-to-end high-throughput discovery workflow that enables faster, lower-cost "fail fast" development. Recent platform improvements have reduced lead identification library size by 1000X, and the company previously delivered IND-enabling programs in under 2.5 years for less than $15 million, with additional efficiency gains expected going forward. Atlas has already independently identified genetic evidence linking the prolactin pathway to both pattern hair loss and endometriosis.
Guidance
- Cash runway: The company's current cash position is sufficient to fund all planned operating activities into the second half of 2028, up from prior projections that did not include the proceeds from the June 2026 financing. - Clinical timelines: Management reaffirmed prior guidance: interim proof-of-concept 13-week data for ABS-201 in pattern hair loss in H2 2026, full 26-week proof-of-concept data in early 2027, initiation of ABS-201 Phase 2 for endometriosis in Q4 2026, and an endometriosis proof-of-concept readout in H2 2027. Additional details for the endometriosis clinical development plan will be released in Q3 2026. - Market opportunity: Management maintained its prior TAM estimates: >$25 billion for pattern hair loss in the U.S. alone, and a >$4 billion peak sales opportunity for ABS-201 in endometriosis. The name change from androgenetic alopecia to pattern hair loss does not alter the size of the target market or patient population. - Corporate strategy: The company updated its strategic approach to new pipeline assets: all new programs are now developed with the option for independent commercialization in mind, rather than a default plan to outlicense prior to clinical development. Partnerships will only be pursued for programs that do not meet ROI thresholds for internal development or fit complementary commercial positioning alongside existing pipeline assets.
Segment performance
Abcide is a clinical-stage biotech, and all current operating activity supports pipeline development of its lead candidate ABS-201 and preclinical programs, with no product segments generating revenue. Q2 2026 operating expenses: research and development (R&D) expenses were $22.6 million (vs. $20.5 million in the year-ago quarter), an increase driven by advancement of ABS-201 preclinical and clinical development, partially offset by lower personnel costs. Selling, general, and administrative (SG&A) expenses were $9.2 million (vs. $8.5 million in the year-ago quarter), an increase driven by higher stock-based compensation and other administrative overhead. As of June 30, 2026, total cash, cash equivalents, and marketable securities were $201.1 million, up from $125.7 million at the end of Q1 2026 following the $100 million financing completed in June 2026.
Risks & headwinds
- All forward-looking statements, including clinical trial timelines, expected efficacy, receptor occupancy projections, and market opportunity estimates, are subject to material risks and uncertainties that could cause actual results to differ materially from projections. Key risks include potential failure to meet safety or efficacy endpoints in ongoing or future clinical trials, delays in patient enrollment, regulatory review delays, and failure to obtain regulatory approval for ABS-201 or other pipeline candidates. - The company's regenerative mechanism of action for ABS-201 has only been demonstrated in preclinical and ex vivo studies, and there is no guarantee the same effect will be observed in human clinical trials. - 13-week interim data will not include any readout on the durability of ABS-201's hair growth effect, which will require longer-term patient follow-up that has not yet been completed. - Competitive landscape changes, including new data from competing pattern hair loss therapies, could alter the expected market opportunity and commercial positioning of ABS-201. - The company depends on the performance of its AI platform to deliver new, high-quality pipeline candidates at lower cost, and expected efficiency gains may not materialize as projected.
Analyst Q&A
Q: The company changed the lead indication name from androgenetic alopecia to pattern hair loss. Does this reflect a change in the actual indication or target patient population? /
A: The underlying indication and target patient population remain unchanged. The name was updated for three reasons: it better reflects the unique prolactin receptor mechanism (which acts upstream of the androgen receptor targeted by existing treatments), it is a more inclusive term that covers both male and female patients, and it is more easily understood by consumers. The name change does not alter the company's estimated market opportunity. (3-4 sentences)
Q: What is the company's expected terminal-to-vellus hair ratio threshold for the 13-week interim readout, and how does that compare to existing therapies? /
A: Management is not targeting a specific terminal-to-vellus ratio for the interim readout, and no definitive public data on this metric from competing programs is available to benchmark against. The company focuses on total target area hair count as the primary endpoint, which captures all changes including transitions from vellus to terminal hair and regrowth in previously dormant follicles, the key unique benefit of the company's regenerative mechanism. (3-4 sentences)
Q: What will the company disclose in the 13-week interim top-line readout, and when will data on durability of effect be available? /
A: The 13-week release will include target area terminal hair count, hair caliber width, hair darkness, and updated safety and tolerability data. Durability of effect will not be available at 13 or 26 weeks; initial durability data will come from the trial's mandatory post-treatment safety follow-up period, with longer-term durability data to be collected and released after that. (3-4 sentences)
Q: How does ABS-201's sustained >90% receptor occupancy differentiate it from other prolactin receptor antibody candidates? /
A: Prior candidate HMI 115 only achieved 60-70% fluctuating receptor occupancy with frequent dosing, which the company believes is why it failed to deliver meaningful efficacy. The prolactin receptor requires >90% sustained occupancy to fully block signaling, which allows hair follicles to remain in the growth phase long enough to regenerate the stem cell niche. This same principle applies to endometriosis, where the company believes high sustained occupancy will deliver better efficacy than what was seen with prior low-occupancy candidates. (4 sentences)